HUYA’s COMPOUND PORTFOLIO

HUYA’s strategy is to identify and license early stage lead compounds with promising efficacy and toxicity data in laboratory and animal models.  HUYA has performed preliminary diligence of drug candidates in China from various sources to find the most promising compounds to bring to the Western markets. HUYA is building a portfolio of more than 500 compounds in fields that include: Biologics, Metabolic Diseases, Endocrinology, Cardiology/Pulmonary, Gastroenterology, Infectious Diseases, Neurology, Immunology, Oncology as well as drugs from Traditional Chinese Medicines. [read more]